



## Consolidated Financial Results for the Fiscal Year Ended December 31, 2021 [Japanese GAAP]

February 14, 2022

Listing: Tokyo Stock Exchange

Company name: Medical Data Vision Co., Ltd.

Securities code: 3902 URL <https://www.mdv.co.jp/>

Representative: (Title) President

(Name) Hiroyuki Iwasaki

Inquiries: (Title) Executive Officer and General Manager of  
Corporate Planning Division

(Name) Masahiro Kihara

Tel: +81-3-5283-6911

Scheduled date of annual general meeting of shareholders: March 29, 2022

Scheduled date to commence dividend payments: March 30, 2022

Scheduled date to file annual securities report: March 29, 2022

Preparation of supplementary material on financial results : Yes

Holding of financial results briefing : Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted)

1. Consolidated financial results for the fiscal year ended December 31, 2021 (from January 1, 2021 to December 31, 2021)

### (1) Consolidated operating results

(Percentages indicate year-on-year changes)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Fiscal year ended December 31, 2021	5,672	23.9	1,594	39.1	1,592	38.7	1,087	55.3
Fiscal year ended December 31, 2020	4,579	13.7	1,146	41.6	1,148	42.7	700	26.3

(Note) Comprehensive income Fiscal year ended December 31, 2021 ¥1,100 million [56.6%]  
Fiscal year ended December 31, 2020 ¥702 million [28.7%]

	Basic earnings per share	Diluted earnings per share	Return on equity	Ratio of ordinary income to total assets	Ratio of operating income to net sales
	Yen	Yen	%	%	%
Fiscal year ended December 31, 2021	27.74	—	26.3	29.3	28.1
Fiscal year ended December 31, 2020	17.72	—	17.3	22.4	25.0

(Reference) Share of profit (loss) of entities accounted for using equity method Fiscal year ended December 31, 2021 — million yen  
Fiscal year ended December 31, 2020 — million yen

(Note) Diluted earnings per share for the fiscal year ended December 31, 2020 and fiscal year ended December 31, 2021 are not presented as there are no potentially dilutive shares.

### (2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
Fiscal year ended December 31, 2021	5,534	4,205	75.1	106.69
Fiscal year ended December 31, 2020	5,321	4,136	77.0	104.00

(Reference) Equity Fiscal year ended December 31, 2021 4,156 million yen  
Fiscal year ended December 31, 2020 4,100 million yen

### (3) Consolidated cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at end of period
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Fiscal year ended December 31, 2021	1,082	-26	-1,030	3,202
Fiscal year ended December 31, 2020	964	-142	-589	3,177

## 2. Cash dividends

	Annual dividends per share					Total cash dividends (total)	Payout ratio (consolidated)	Ratio of dividends to net assets (consolidated)
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total			
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Fiscal year ended December 31, 2020	—	0.00	—	3.60	3.60	141	20.3	3.4
Fiscal year ended December 31, 2021	—	0.00	—	5.60	5.60	218	20.1	5.2
Fiscal year ending December 31, 2022 (forecast)	—	0.00	—	6.00	6.00		20.9	

(Note) For dividends as of the end of the fiscal year ended December 31, 2021, please refer to “Notice Concerning the Dividends of Surplus (Increase in Dividend)” announced today.

## 3. Consolidated earnings forecasts for the fiscal year ending December 31, 2022 (from January 1, 2022 to December 31, 2022)

(Percentages indicate year-on-year changes)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	6,300	—	1,599	—	1,600	—	1,098	—	28.74

(Notes) 1. The Accounting Standard for Revenue Recognition (ASBJ Statement No. 29) and related implementation guidance will be applied from the beginning of the fiscal year ending December 2022. The above consolidated earnings forecasts therefore are the amount after applying such accounting standard and related implementation guidance, presenting no year-on-year changes.

2. The Company purchased 763,400 treasury shares from January 1, 2022 to January 25, 2022 based on the resolution of the Board of Directors held on December 22, 2021. Basic earnings per share for the consolidated earnings forecasts takes into account the impact of the purchase of treasury shares.

### \* Notes

(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in changes in scope of consolidation): None

Newly included: — companies (Company name), Excluded: — companies (Company name)

(2) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations : None

(ii) Changes in accounting policies due to other reasons : None

(iii) Changes in accounting estimates : None

(iv) Restatement : None

(3) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)	As of December 31, 2021	40,027,526 shares	As of December 31, 2020	40,027,526 shares
(ii) Number of treasury shares at the end of the period	As of December 31, 2021	1,067,278 shares	As of December 31, 2020	601,529 shares
(iii) Average number of shares outstanding during the period	Fiscal year ended December 31, 2021	39,188,537 shares	Fiscal year ended December 31, 2020	39,507,964 shares

(Reference) Overview of non-consolidated financial results

Non-consolidated financial results for the fiscal year ended December 31, 2021 (from January 1, 2021 to December 31, 2021)

(1) Non-consolidated operating results

(Percentages indicate year-on-year changes)

	Net sales		Operating income		Ordinary income		Net income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Fiscal year ended December 31, 2021	4,695	16.0	1,523	36.8	1,521	36.6	1,048	57.2
Fiscal year ended December 31, 2020	4,047	6.7	1,113	30.2	1,114	30.0	667	11.3

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Fiscal year ended December 31, 2021	26.76	—
Fiscal year ended December 31, 2020	16.89	—

(Note) Diluted earnings per share for the fiscal year ended December 31, 2020 and fiscal year ended December 31, 2021 are not presented as there are no potential shares.

(2) Non-consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
Fiscal year ended December 31, 2021	5,342	4,264	79.8	109.46
Fiscal year ended December 31, 2020	5,177	4,246	82.0	107.71

(Reference) Equity      Fiscal year ended December 31, 2021    ¥4,264 million      December 31, 2020    ¥4,246 million

\* Financial results reports are exempt from an audit conducted by certified public accountants or an audit corporation.

\* Proper use of earnings forecasts, and other special matters

The forward-looking statements, including earnings forecasts, contained in this material are based on information currently available to the Group and on certain assumptions deemed to be reasonable. Actual business and other results may differ substantially due to a range of factors.

### 3. Consolidated financial statements and key notes

#### (1) Consolidated balance sheet

(Thousands of yen)

	Previous fiscal year (December 31, 2020)	Current fiscal year (December 31, 2021)
<b>Assets</b>		
<b>Current assets</b>		
Cash and deposits	3,194,305	3,221,790
Accounts receivable - trade	867,779	1,058,670
Raw materials	34,167	11,253
Other	224,611	235,643
Allowance for doubtful accounts	-1,688	-2,268
Total current assets	4,319,174	4,525,088
<b>Non-current assets</b>		
<b>Property, plant and equipment</b>		
Facilities attached to buildings, net	81,776	70,171
Tools, furniture and fixtures, net	93,570	69,170
Other, net	2,283	719
Total property, plant and equipment	* 177,630	* 140,061
<b>Intangible assets</b>		
Software	8,528	5,088
Goodwill	294,640	222,367
Other	192	192
Total intangible assets	303,362	227,649
<b>Investments and other assets</b>		
Investment securities	34,896	34,896
Deferred tax assets	231,765	308,618
Other	281,715	324,320
Allowance for doubtful accounts	-26,766	-25,927
Total investments and other assets	521,611	641,907
Total non-current assets	1,002,604	1,009,618
<b>Total assets</b>	5,321,778	5,534,706

(Thousands of yen)

	Previous fiscal year (December 31, 2020)	Current fiscal year (December 31, 2021)
<b>Liabilities</b>		
Current liabilities		
Accounts payable - trade	76,014	97,266
Income taxes payable	298,866	400,206
Unearned revenue	323,799	353,382
Provision for bonuses	78,993	28,858
Other	322,314	363,845
Total current liabilities	1,099,987	1,243,559
Non-current liabilities		
Asset retirement obligations	72,218	72,509
Other	12,744	12,778
Total non-current liabilities	84,962	85,288
Total liabilities	1,184,949	1,328,848
Net assets		
Shareholders' equity		
Share capital	992,661	992,661
Capital surplus	1,763,567	1,763,567
Retained earnings	1,934,389	2,879,722
Treasury shares	-590,371	-1,479,444
Total shareholders' equity	4,100,247	4,156,506
Non-controlling interests	36,581	49,351
Total net assets	4,136,828	4,205,858
Total liabilities and net assets	5,321,778	5,534,706

(2) Consolidated statement of income and consolidated statement of comprehensive income

(Consolidated statement of income)

(Thousands of yen)

	Previous fiscal year (From January 1, 2020 to December 31, 2020)	Current fiscal year (From January 1, 2021 to December 31, 2021)
Net sales	4,579,731	5,672,300
Cost of sales	697,298	1,028,541
Gross income	3,882,433	4,643,759
Selling, general and administrative expenses	2,736,037	3,049,540
Operating income	1,146,395	1,594,218
Non-operating income		
Interest income	22	30
Subsidy income	2,200	126
Reversal of allowance for doubtful accounts	—	839
Other	212	122
Total non-operating income	2,435	1,118
Non-operating expenses		
Commission expenses	651	2,236
Other	76	110
Total non-operating expenses	728	2,346
Ordinary income	1,148,103	1,592,990
Extraordinary losses		
Loss on sale of non-current assets	—	527
Loss on retirement of non-current assets	1,089	566
Impairment losses	* 70,418	—
Total extraordinary losses	71,508	1,094
Net income before income taxes	1,076,595	1,591,896
Income taxes - current	388,854	568,676
Income taxes - deferred	-14,772	-76,818
Total income taxes	374,082	491,858
Net income	702,512	1,100,038
Net income attributable to non-controlling interests	2,292	12,770
Net income attributable to owners of parent	700,220	1,087,267

(Consolidated statement of comprehensive income)

(Thousands of yen)

	Previous fiscal year (From January 1, 2020 to December 31, 2020)	Current fiscal year (From January 1, 2021 to December 31, 2021)
Net income	702,512	1,100,038
Comprehensive income	702,512	1,100,038
Comprehensive income attributable to:		
Owners of parent	700,220	1,087,267
Non-controlling interests	2,292	12,770

(3) Consolidated statement of changes in equity  
 Previous fiscal year (from January 1, 2020 to December 31, 2020)

(Thousands of yen)

	Shareholders' equity					Non-controlling interests	Total net assets
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity		
Balance at beginning of period	992,661	1,756,245	1,241,490	-726	3,989,671	34,289	4,023,960
Changes during period							
Transfer from retained earnings to capital surplus		7,321	-7,321		—		—
Net income attributable to owners of parent			700,220		700,220		700,220
Purchase of treasury shares				-589,644	-589,644		-589,644
Net changes in items other than shareholders' equity						2,292	2,292
Total changes during period	—	7,321	692,898	-589,644	110,576	2,292	112,868
Balance at end of period	992,661	1,763,567	1,934,389	-590,371	4,100,247	36,581	4,136,828

Current fiscal year (from January 1, 2021 to December 31, 2021)

(Thousands of yen)

	Shareholders' equity					Non-controlling interests	Total net assets
	Share capital	Capital surplus	Retained earnings	Treasury shares	Total shareholders' equity		
Balance at beginning of period	992,661	1,763,567	1,934,389	-590,371	4,100,247	36,581	4,136,828
Changes during period							
Dividends of surplus			-141,934		-141,934		-141,934
Net income attributable to owners of parent			1,087,267		1,087,267		1,087,267
Purchase of treasury shares				-889,073	-889,073		-889,073
Net changes in items other than shareholders' equity						12,770	12,770
Total changes during period	—	—	945,332	-889,073	56,258	12,770	69,029
Balance at end of period	992,661	1,763,567	2,879,722	-1,479,444	4,156,506	49,351	4,205,858



(4) Consolidated statement of cash flows

(Thousands of yen)

	Previous fiscal year (From January 1, 2020 to December 31, 2020)	Current fiscal year (From January 1, 2021 to December 31, 2021)
<b>Cash flows from operating activities</b>		
Net income before income taxes	1,076,595	1,591,896
Depreciation	87,786	63,280
Amortization of goodwill	71,012	72,272
Impairment losses	70,418	—
Increase (decrease) in allowance for doubtful accounts	820	-259
Increase (decrease) in provision for bonuses	-27,117	-50,134
Interest income	-22	-30
Loss on sale of non-current assets	—	527
Loss on retirement of non-current assets	1,089	566
Share-based payment expenses	8,351	1,874
Decrease (increase) in trade receivables	-95,481	-190,890
Decrease (increase) in inventories	1,069	24,497
Increase (decrease) in trade payables	-207	21,252
Increase (decrease) in accounts payable - other	30,125	16,464
Increase (decrease) in accrued expenses	-3,231	-31,847
Increase (decrease) in unearned revenue	15,938	29,583
Other	-47,998	5,485
Subtotal	1,189,149	1,554,538
Interest and dividends received	22	30
Income taxes refund (paid)	-224,805	-471,953
Net cash provided by (used in) operating activities	964,366	1,082,616
<b>Cash flows from investing activities</b>		
Payments into time deposits	—	-20,418
Proceeds from withdrawal of time deposits	—	18,016
Purchase of property, plant and equipment	-25,074	-24,040
Purchase of intangible assets	-1,977	—
Purchase of shares of subsidiaries resulting in change in scope of consolidation	-108,024	—
Payments of leasehold deposits	-7,511	-4,224
Proceeds from refund of leasehold deposits	292	2,319
Other	-288	1,412
Net cash provided by (used in) investing activities	-142,583	-26,933
<b>Cash flows from financing activities</b>		
Purchase of treasury shares	-589,644	-889,073
Dividends paid	—	-141,524
Net cash provided by (used in) financing activities	-589,644	-1,030,598
Net increase (decrease) in cash and cash equivalents	232,138	25,083
Cash and cash equivalents at beginning of period	2,944,950	3,177,088
Cash and cash equivalents at end of period	3,177,088	3,202,172

(5) Notes to consolidated financial statements  
 (Notes to assumptions for on going concerns)  
 Not applicable

(Consolidated balance sheet)

\* Accumulated depreciation of property, plant and equipment is as follows:

	Previous fiscal year (From January 1, 2020 to December 31, 2020)	Current fiscal year (From January 1, 2021 to December 31, 2021)
Accumulated depreciation of property, plant and equipment	465,150 (thousands of yen)	501,476 (thousands of yen)

(Consolidated statement of income)

\* Details of impairment losses are as follows:

Previous fiscal year (from January 1, 2020 to December 31, 2020)

The Group recorded impairment losses on the following asset groups.

Location	Application	Type	Amount (thousands of yen)
Chiyoda-ku, Tokyo	Business assets	Facilities attached to buildings, etc.	2,150
Chiyoda-ku, Tokyo	Business assets	Software	1,103
Chiyoda-ku, Tokyo	Other	Goodwill	67,165

In principle, the Group groups its assets according to the category of management accounting based on business units. However, assets that are not likely to be used in the future or for which a decision has been made to dispose of or discontinue them are grouped individually.

For some consolidated subsidiaries engaged in the development and sales of medical systems, revenues originally anticipated are unlikely to be generated. On this account, the book value of goodwill, etc. on such business is recorded in full amount as impairment losses.

The recoverable amount of the said asset group is measured by the value in use. Since negative future cash flows are expected, the recoverable amount is calculated as zero.

Current fiscal year (from January 1, 2021 to December 31, 2021)

Not applicable

(Segment information, etc.)

Segment information

Segment information is omitted as the Group is comprised of a single segment of the medical data network business.

(Per-share information)

	Previous fiscal year (From January 1, 2020 to December 31, 2020)	Current fiscal year (From January 1, 2021 to December 31, 2021)
Net assets per share	104.00 yen	106.69 yen
Basic earnings per share	17.72 yen	27.74 yen

(Notes) 1. Diluted earnings per share are not presented as there are no potentially dilutive shares.

2. The calculation basis for basic earnings per share is as follows:

	Previous fiscal year (From January 1, 2020 to December 31, 2020)	Current fiscal year (From January 1, 2021 to December 31, 2021)
Basic earnings per share		
Net income attributable to owners of parent (thousands of yen)	700,220	1,087,267
Amount not attributable to common shareholders (thousands of yen)	—	—
Net income attributable to owners of parent concerning common shares (thousands of yen)	700,220	1,087,267
Average number of shares outstanding during the period (shares)	39,507,964	39,188,537

(Important subsequent events)

(Purchase of treasury shares)

The Company resolved at the Board of Directors held on December 22, 2021 to purchase treasury shares pursuant to the provisions of Article 459, paragraph (1) of the Companies Act and Article 42 of the Company's Articles of Incorporation.

1. Reasons for the purchase of treasury shares

Treasury shares are purchased to improve shareholder profits through enhancement of capital efficiency, implement flexible capital policies such as M&A, and secure talented human resources by utilizing incentive plans for directors and employees.

2. Details of matters regarding purchase

- |   |  |
|---|--|
| (1) Class of shares for purchase        | Common stock of the Company  |
| (2) Total number of shares for purchase | 800,000 shares (maximum)<br>(2.05% of total number of issued shares (excluding treasury shares)) |
| (3) Total amount of shares for purchase | ¥1,000,000,000 (maximum)   |
| (4) Purchase period                     | From December 23, 2021 to June 30, 2022  |
| (5) Purchase method                     | Market purchase through the Tokyo Stock Exchange   |

3. Status of purchase of treasury shares

- |   |  |
|---|--|
| (1) Class of shares for purchase        | Common stock of the Company                      |
| (2) Total number of shares purchased    | 763,400 shares                                   |
| (3) Total amount of shares for purchase | 862,530 (thousands of yen)                       |
| (4) Purchase period                     | From January 1, 2022 to January 25, 2022         |
| (5) Purchase method                     | Market purchase through the Tokyo Stock Exchange |

4. Acquisition Result

As a result of the above purchase, the Company acquired 800,000 shares of common stock of the Company at a purchase price of 906,611 (thousands of yen) by January 25, 2022, and completed the purchase of treasury stock in accordance with this resolution.

(Acquisition of Companies, etc. through Acquisition of Shares)

At a meeting of the Board of Directors held on February 14, 2022, we resolved to acquire the shares of AIR BIOS Co., Ltd. ("AIR BIOS") and make it a consolidated subsidiary, and concluded a share transfer contract on the same day.

1. Purpose of share acquisition

Since its foundation, the Group has been promoting its business with the aim of "contributing to the creation of benefits for consumers by promoting the unification and utilization of healthcare and health information." We believe that the unification of medical and health information, including hospitals, clinics, nursing care facilities, and other facilities, creates an environment in which patients can manage and view their own medical history and health conditions, and also contributes to further improvements in the quality of healthcare through data analysis.

AIR BIOS, which is now a consolidated subsidiary, develops healthcare-related systems, develops cancer screening testing methods, and engages in regenerative medicine. Going forward, we will collaborate with AIR BIOS, which has strengths in cancer screening tests with healthcare institutions. In this way, we will not only acquire sales in these areas, but also strengthen our group's information assets by acquiring data at the time of testing. We expect to utilize more diverse medical big data by collecting information not only in disease areas in which we have strengths, but also in non-disease areas in a complex manner.

2. Overview of the company to be acquired

Name	AIR BIOS Co., Ltd.
Business Activities	Develop new treatments and medical services Development of medical-related systems and robots Development and operation monitoring of medical infrastructure
Capital	20,000 (thousands of yen)

3. Time of stock acquisition

February 18, 2022 (planned)

4. Number of shares to be acquired, acquisition price, and ownership ratio after acquisition

Number of shares to be acquired	650 shares of common stock
Acquisition price	Acquisition price is not disclosed based on agreement between the parties, but the fair value is calculated.
Equity after acquisition	50%

5. Method of raising funds for payment

Own funds

4. Other

(1) Changes in officers (expected on March 29, 2022)

(i) Change in representative directors

Not applicable

(ii) Change in other officers

• New expected Corporate Auditor

Masaaki Takaki      Outside Corporate Auditor

(2) Other

Not applicable